Home/Pipeline/Personalized Regenerative Therapies

Personalized Regenerative Therapies

Broad portfolio including Lung Disease, Macular Degeneration, Alzheimer’s, Parkinson’s, Diabetes, Kidney Disease, etc.

Pre-clinical/R&DActive

Key Facts

Indication
Broad portfolio including Lung Disease, Macular Degeneration, Alzheimer’s, Parkinson’s, Diabetes, Kidney Disease, etc.
Phase
Pre-clinical/R&D
Status
Active
Company

About Cellino Biotech

Cellino Biotech is pioneering a closed-loop, autonomous manufacturing platform to scale personalized regenerative therapies. The company's proprietary technology stack combines AI, laser-based cell editing, and modular hardware (Nebula™) to overcome key bottlenecks in cell therapy: reproducibility, scalability, and the need for immunosuppression. By enabling distributed manufacturing of patient-specific iPSC-derived therapies, Cellino targets a broad pipeline of chronic degenerative conditions, positioning itself at the convergence of deep tech and biomedicine. The company is privately held and appears to be in a pre-clinical or platform development stage.

View full company profile